Virtua Voorhees Hospital

Peroral endoscopic myotomy (POEM) is a standard achalasia treatment, matching surgery in efficacy. However, myotomy length varies. Shorter myotomies are gaining attention for potential benefits. This study compares short versus long myotomies to identify the optimal approach. We conducted a systematic review and meta-analysis of Randomized Controlled Trials (RCTs) retrieved from PubMed (MEDLINE), Scopus, Web of Science (WoS), and Cochrane Central Register of Controlled Trials (CENTRAL) until November 28, 2024. Pooled results were calculated using risk ratios (RR) for binary outcomes and mean differences (MD) for continuous outcomes, with 95% CI (PROSPERO ID: CRD42024621638). Four RCTs with 419 patients were included. Clinical success (Eckardt score ≤3) showed no significant difference between short and long myotomy (97.4% vs. 95.9%, RR: 1.02 with 95% CI: 0.98-1.06, P =0.33), Reflux symptoms (RR: 0.93, 95% CI: 0.60-1.47, P =0.77), and reflux esophagitis (RR: 0.83, 95% CI: 0.55-1.27, P =0.39). However, short myotomy significantly reduced pathologic acid exposure (RR: 0.57, 95% CI: 0.36-0.91, P =0.02), procedural time (MD: -16.61min, 95% CI: -26.40 to -6.81, P <0.001), and hospital stay (MD: -2.37d, 95% CI: -4.67 to -0.06, P =0.04). Intraprocedural complications were similar ( P =0.73), as was integrated relaxation pressure ( P =0.95), indicating similar postoperative esophageal function. Short myotomy reduced acid exposure, procedure time, and hospital stay in POEM for achalasia without compromising clinical success or symptom improvement. It shows potential as an effective treatment, but large-scale RCTs are needed for definitive clinical endorsement.

Introduction: Hypertension (HTN) is a common condition at the focus of global health efforts. While great strides have been made towards the treatment and diagnosis of this condition, its relationship with the gut microbiome requires further investigation. We sought to assess the impact of HTN on various conditions associated with alterations of the gut microbiome. Methods: A retrospective analysis was completed utilizing the NIS. Patients were identified based on ICD-10 codes corresponding to those with essential hypertension (HTN) alone vs those with HTN and a gut microbiome disease (GMD). These included ulcerative colitis (UC), gastroparesis, clostridium difficile (C. diff), irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO). Primary outcomes were mortality, (mean length of stay (LOS) and total hospital charge (TOTCHG). Results: Of 8,667,791 patients with HTN, 39,280 had UC, 81,085 had gastroparesis, 9,285 had C. diff, 110,320 had IBS, and 12,295 had SIBO. Patients with HTN and GMD had an OR of 0.65 (CI 0.63-0.67, p = 0.00). Native Americans with concurrent HTN and GMD had an OR of 1.56 (CI 1.33-1.83, p = 0.00). LOS was increased in patients with HTN and concurrent gastroparesis and C. diff (Table 1). Having Medicare, Medicaid, being admitted with UC, gastroparesis or C. diff and being of asian or hispanic heritage were significantly associated with higher costs. Conclusion: HTN in the presence of a disease associated with alteration of the gut microbiome does not demonstrate a negative effect on mortality. It does, however, demonstrate increased mortality in Native American populations as well as increased LOS in gastroparesis and C. diff.

e13607 Background: Randomized clinical trials of multi-cancer early detection (MCED) tests are being planned, and primary care providers (PCPs) are likely to encounter patients who are considering participation. Little information has been reported about provider support for patient participation in such trials. Methods: We surveyed PCPs from 4 practices in a large health system to learn about their views on patient participation in a hypothetical MCED test trial. The PCPs received a link to view a patient-oriented infographic that described a trial in which participants would undergo serial blood draws for MCED testing and would be randomly assigned either to standard care or to receive MCED test results and follow-up, as needed. After viewing the infographic, respondents were asked to complete a brief survey that included statements related to factors that would affect their receptivity to patient participation in the trial, using a 5-point Likert type response scale that ranged from 1 = Strongly Disagree to 5 = Strongly Agree. The survey also included a single item that asked respondents if they would support patient participation in the trial and provided an opportunity to report the main reason for their answer. Finally, the survey contained a background characteristics section. We computed frequency distributions of survey responses. Results: Twenty-seven of 37 (73%) invited primary care providers completed the survey. About half of the respondents were women and two thirds were white; 81% were physicians while 19% were nurse practitioners, 54% were in practice for less than 20 years, all were board certified, and 74% had a hospital affiliation. Receptivity scores regarding a future MCED trial were high, with a mean of 3.8 and standard deviation of 0.6. Overall, 25 providers (93%) reported that they would support patient participation in an MCED test trial. The most commonly reported reasons for supporting patient participation were the belief that early cancer detection is important and the belief that research to develop new cancer screening tests is needed. The most commonly cited reasons for not supporting participation were concern about managing patients diagnosed with cancer in the trial and worry that trial participants would require too many practice resources. Conclusions: The overwhelming majority of respondents supported patient participation in an MCED test trial, but many were concerned about trial impact on their capacity to meet patient needs. Further research is needed in a larger study to validate these results and learn more about factors likely to influence PCP support for patient participation in MCED test trials and actual participation.

Behavior observation is an integral component in the field of applied behavior analysis (ABA) when supporting individuals diagnosed with autism spectrum disorder (ASD). In this chapter, we unpack the importance of selecting target behaviors, precisely defining target behaviors, and measuring target behaviors when designing behavior analytic assessment and intervention. We describe common strategies that are used to measure behavior including direct methods, derivative measures, and time sampling. Moreover, crucial elements of optimum behavior measurement including reliability, accuracy, and validity are delineated. Last, we describe strategies for calculating interobserver agreement (IOA), unpack differences, and highlight their importance when supporting individuals with ASD.

Introduction: Medullary carcinoma of the colon (MAC) is a rare cancer encompassing only .03% of all colorectal carcinomas. We present a rare case of MAC occurring in an older adult with a strong tobacco use history. Case Description/Methods: A 76-year-old female with PMHx of tobacco use disorder, COPD, and known pulmonary nodules presented to the ED for surveillance of her pulmonary nodules. A review of systems was positive for chronic shortness of breath and cough. A CT scan of the chest revealed enlarging lung nodules and mediastinal adenopathy. A PET scan revealed a hypermetabolic 2.5 x 2.5 cm soft mass in the distal ascending colon and hypermetabolic lymph nodes in the right upper quadrant (Figure). Colonoscopy revealed an infiltrative 2 cm mass at the hepatic flexure, and pathology revealed an invasive, poorly differentiated adenocarcinoma with normal expression of MSH2 and MSH6 and absence of MLH1 and PMS2. These findings were consistent with medullary carcinoma of the colon. Endoscopic ultrasound with biopsy of peripancreatic and porta-hepatis lymph nodes favored metastatic medullary carcinoma. The patient underwent a right hemicolectomy and follows closely outpatient. Discussion: MAC is a rare cancer associated with a high level of microsatellite instability and deficient mismatch repair proteins. It is a non-gland forming cancer composed of large polygonal eosinophilic cells growing in solid sheets and infiltrated with small lymphocytes. The majority of reported cases revealed a lack of MLH-1 and PMS2, just as our patient did. They instead express markers that are not commonly associated with colorectal cancers, such as calretinin, CK7, SATB2, and CDH17. MACs were previously difficult to differentiate from poorly differentiated adenocarcinomas due to their unique tumor marker expression and histopathology. The current standard for diagnosis of MAC therefore requires distinct microscopic morphology and molecular staining patterns. There are no current treatment guidelines due to the rarity of MACs, although MACs do have a favorable prognosis when compared to other adenocarcinomas and surgical resection and FOLFOX chemotherapy have been used successfully in some studies. Although MACs have been sporadically reported in case reports, further studies are required to determine guidelines for both diagnosis and treatment of this rare disease.Figure 1.: Endoscopic Visualization with Final Needle Aspiration of Abnormal Lymph Node.

Abstract LTT 1445 is a hierarchical triple M-dwarf star system located at a distance of 6.86 pc. The primary star LTT 1445A (0.257 M ⊙) is known to host the transiting planet LTT 1445Ab with an orbital period of 5.36 days, making it the second-closest known transiting exoplanet system, and the closest one for which the host is an M dwarf. Using Transiting Exoplanet Survey Satellite data, we present the discovery of a second planet in the LTT 1445 system, with an orbital period of 3.12 days. We combine radial-velocity measurements obtained from the five spectrographs, Echelle Spectrograph for Rocky Exoplanets and Stable Spectroscopic Observations, High Accuracy Radial Velocity Planet Searcher, High-Resolution Echelle Spectrometer, MAROON-X, and Planet Finder Spectrograph to establish that the new world also orbits LTT 1445A. We determine the mass and radius of LTT 1445Ab to be 2.87 ± 0.25 M ⊕ and 1.304 − 0.060 + 0.067 R ⊕, consistent with an Earth-like composition. For the newly discovered LTT 1445Ac, we measure a mass of 1.54 − 0.19 + 0.20 M ⊕ and a minimum radius of 1.15 R ⊕, but we cannot determine the radius directly as the signal-to-noise ratio of our light curve permits both grazing and nongrazing configurations. Using MEarth photometry and ground-based spectroscopy, we establish that star C (0.161 M ⊙) is likely the source of the 1.4 day rotation period, and star B (0.215 M ⊙) has a likely rotation period of 6.7 days. We estimate a probable rotation period of 85 days for LTT 1445A. Thus, this triple M-dwarf system appears to be in a special evolutionary stage where the most massive M dwarf has spun down, the intermediate mass M dwarf is in the process of spinning down, while the least massive stellar component has not yet begun to spin down.

Abstract We report the discovery of TOI-2180 b, a 2.8 M J giant planet orbiting a slightly evolved G5 host star. This planet transited only once in Cycle 2 of the primary Transiting Exoplanet Survey Satellite (TESS) mission. Citizen scientists identified the 24 hr single-transit event shortly after the data were released, allowing a Doppler monitoring campaign with the Automated Planet Finder telescope at Lick Observatory to begin promptly. The radial velocity observations refined the orbital period of TOI-2180 b to be 260.8 ± 0.6 days, revealed an orbital eccentricity of 0.368 ± 0.007, and discovered long-term acceleration from a more distant massive companion. We conducted ground-based photometry from 14 sites spread around the globe in an attempt to detect another transit. Although we did not make a clear transit detection, the nondetections improved the precision of the orbital period. We predict that TESS will likely detect another transit of TOI-2180 b in Sector 48 of its extended mission. We use giant planet structure models to retrieve the bulk heavy-element content of TOI-2180 b. When considered alongside other giant planets with orbital periods over 100 days, we find tentative evidence that the correlation between planet mass and metal enrichment relative to stellar is dependent on orbital properties. Single-transit discoveries like TOI-2180 b highlight the exciting potential of the TESS mission to find planets with long orbital periods and low irradiation fluxes despite the selection biases associated with the transit method.